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Abstract 
Background 
Variant Creutzfeldt-Jakob disease (vCJD) is a transmissible spongiform encephalopathy 
(TSE) affecting humans, acquired initially through infection with bovine spongiform 
encephalopathy (BSE). A small number of vCJD cases have been acquired through the 
transfusion of blood from asymptomatic donors who subsequently developed vCJD. Filter 
devices that selectively bind the infectious agent associated with prion disease have been 
developed for removal of infection from blood. This study independently assessed one such 
filter, the P-CAPT filter, for efficacy in removing infectivity associated with the BSE agent in 
sheep blood. The sheep BSE model has previously been used to evaluate the distribution of 
infectivity in clinically-relevant blood components. This is the first study to assess the ability 
of the P-CAPT filter to remove endogenous infectivity associated with blood components 
prepared from a large animal model.  
Methods 
Paired units of leucoreduced red cell concentrates (LR-RCC) were prepared from donors at 
the clinical stage of infection and confirmed as having BSE. One cohort of recipients was 
transfused with LR-RCC alone, whereas a parallel cohort received leucoreduced and P-
CAPT-filtered RCC.  
Results 
Out of fourteen recipients, two have been confirmed as having BSE. These sheep had 
received leucoreduced RCC and leucoreduced/P-CAPT-filtered RCC from the same donor. 
Conclusions 
The results indicate that, following leucoreduction and P-CAPT filtration, there can still be 
sufficient residual infectivity in sheep RCC to transmit infection when transfused into a 
susceptible recipient. 
 
Keywords 
Prions, prion filtration, leucoreduction, blood transfusion, red cell concentrates, P-CAPT  
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Introduction 
The identification of variant Creutzfeldt-Jakob disease (vCJD) in humans in 19961,2 is 
believed to be linked to the consumption of meat products from cattle infected with bovine 
spongiform encephalopathy (BSE).3  The UK has shown the highest incidence of vCJD in 
the world with 177 definite or probable cases reported up until 3rd November 2014.4,5 During 
the early stages of the vCJD outbreak, the risk of disease transmission via iatrogenic routes 
such as blood transfusion, organ donation and surgical procedures was unknown. However, 
data from multiple prion-infected models were beginning to show that blood collected before 
the onset of clinical signs could transmit infection following experimental inoculation of 
laboratory hosts.6-13 This was confirmed using large animal models (sheep and deer), which 
have provided convincing evidence that blood transfusion is also an efficient route of prion 
transmission.14-20 
 
The Transfusion Medicine Epidemiology Review (TMER) was set up in 2006 to investigate 
whether there was evidence that Creutzfeldt-Jakob disease (CJD) or vCJD may have been 
transmitted via the blood supply.21 This review has identified three cases of vCJD21-26 in UK 
residents who had been transfused with non-leucodepleted red cell concentrates (RCC) from 
donors who were later confirmed to have died from vCJD. In common with all confirmed 
clinical cases of vCJD to date, these individuals were homozygous for methionine (M) at 
codon 129 of the PRNP gene (129MM).  A fourth recipient of non-leucodepleted RCC, who 
died of causes unrelated to vCJD, but tested positive for disease-associated PrP (PrPd) and 
infectivity in the spleen, was methionine/valine (M/V) heterozygous at codon 129 (129MV).27 
More recently, a 129MV haemophiliac patient who had received Factor VIII prepared from 
plasma pools known to contain donations from a vCJD donor, also tested positive for PrPd in 
spleen samples, but again had no history of neurological disease.28 The latter two cases 
raise the possibility that individuals with 129MV and 129VV genotypes are also susceptible 
to infection with vCJD, but may have longer incubation periods or be asymptomatic carriers 
of infection. This is supported by data from infection of mice transgenic for the human PRNP 
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gene.29 Moreover, recent large-scale surveys of human appendices identified samples from 
individuals of 129MM, 129MV and 129VV genotypes positive for PrPd by 
immunohistochemistry, resulting in prevalence estimates for sub-clinical vCJD infection of up 
to 1 in 2000 of the UK population.30 In the absence of a validated diagnostic test to screen 
for vCJD infection, these asymptomatic individuals present a potential risk for further human-
to-human transmission via iatrogenic routes.  
 
To reduce the likelihood of vCJD transmission via blood products, a number of protective 
measures have been adopted in the UK, including donor deferral, importation of plasma, and 
leucoreduction (filtration to remove white blood cells) of all components used in human 
transfusion medicine.31,32  Continued follow-up in the TMER study has not yet identified any 
evidence of infection in patients who received leucoreduced blood components from known 
vCJD cases. However several experimental models have shown that not all endogenous 
infectivity in blood is removed following leucoreduction.17,33,34 Therefore additional risk 
reduction measures have been considered for the targeted removal of the infectious agent 
(PrPd) from human blood components prior to transfusion or preparation of plasma-derived 
therapeutic products.35-38 One novel approach is prion filtration, which aims to remove 
abnormal PrP from blood by selective binding to affinity ligands or resins, using devices such 
as the MacoPharma P-CAPT filter,33,39,40 the Pall Corporation Leukotrap filter41-43 and the 
Asahi KASEI combination filter.42 Many of the studies evaluating the efficacy of these prion 
reduction filters have used brain spiked into blood or blood components39-41,43 as a way to 
assess the extent of prion removal. However, this approach may not replicate the effects of 
filtration on endogenous infectivity in blood.  
 
The aim of this study was to assess the efficacy of a specific prion removal filter, the CE 
marked P-CAPT filter, in removing endogenous infectivity associated with the BSE agent 
from sheep blood.  The effects of the filter have previously been tested using both spiked40 
and endogenous infectivity33 associated with the 263K hamster scrapie strain. Studies to 
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assess the effect of processing  human leucoreduced red cell concentrates, using the P-
CAPT filter, identified no issues surrounding the clinical safety of P-CAPT-filtered products44 
and found no evidence of adverse effects with respect to component storage, stability, 
viability or other measures of red cell quality.45-48  
 
We have applied the P-CAPT filter to leucoreduced units of red cell concentrates prepared 
from sheep infected with BSE and compared the qualitative effects, in terms of disease 
transmission and detection of abnormal prion protein, with the transfusion of paired units of 
leucoreduced red cells alone. In this sheep model, the distribution of both infectivity and of 
abnormal prion protein in peripheral lymphoid tissues is similar to that of humans affected 
with vCJD.49,50   The relevance of this model in assessing the transfusion-related 
transmission of prion diseases in sheep, has been documented in several publications.14-17 
We have previously shown the presence of infectivity in both red cell concentrates and 
leucoreduced equivalents, when blood was collected from sheep at a pre-clinical stage of 
infection. In this study, we report on infectivity associated with leucoreduced red cell 
concentrates that have been filtered using the P-CAPT filter.  
 
Materials and methods 
Experimental animals 
The animal experiments were approved by The Institute for Animal Health and The Roslin 
Institute's (University of Edinburgh) Animal Welfare and Ethical Review Committees and 
experiments conducted according to the regulations of the UK Home Office Animals 
(Scientific Procedures) Act 1986. 
 
The sheep were sourced from the DEFRA scrapie-free flock51 and were ARQ/ARQ at 
codons 136, 154 and 171 of the sheep PRNP gene (genotypes determined as previously 
described15). The genotypes at codon 141 are indicated in Table 1, whereby the effects 
relate to survival times associated with experimental scrapie and BSE infection 52,53. 
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Donor sheep and blood collection 
For this study, seven sheep were used as blood donors. This cohort was part of a larger 
group of sheep used as blood donors in an ongoing blood transfusion study (referred to as 
the leucodepletion study), and were maintained as previously described.17 Donors were 
orally challenged with 5 g of brain homogenate, prepared from BSE-infected cattle (our 
reference BBB4/5, AHVLA reference SE1909/BBP2) and were clinically monitored until they 
reached defined humane clinical endpoints associated with BSE infection, as previously 
described.15 Immediately before euthanasia, two units of whole blood (WB, 1 unit = 450 ml ± 
10% (v/v)) were collected from each donor into quadruple, bottom and top (BAT) blood 
packs (Fresenius Hemocare, NPBI) fitted with in-line leucoreduction filters, containing 63 ml 
of anti-coagulant CPD.A1 (citrate, phosphate, dextrose, adenine). 
 
Preparation of leucoreduced red cell concentrates (LR-RCC) and leucoreduced and P-
CAPT-filtered red cell concentrates (LR-RCC-P-CAPT)  
The methods of preparing blood components, including P-CAPT-filtered equivalents for 
transfusion were written in conjunction with staff at the Scottish National Blood Transfusion 
Service (SNBTS) to mimic procedures used for the processing of blood from patients and to 
achieve compliance with instructions provided for use of the prion reduction filter. An 
illustrative figure showing the blood collection and component preparation process is shown 
in supplementary figure S1. Immediately after donation (day 0), the 2 whole blood units were 
processed to red cell concentrates, as previously described.17 Red cells were leucoreduced 
(LR-RCC, using the inline T3953 filter) were stored overnight at 4 ºC (without shaking).  
 
The following day (day 1), both LR-RCC units were warmed to 22 ºC and mixed gently using 
a see-saw shaker for 30-60 minutes to ensure homogeneity. The two LR-RCC units were 
then pooled into an oversized blood bag with tubing connected to two separate transfer bags 
(referred to as the Christmas tree configuration pack). This approach was employed to make 
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each of the final products to be transfused as homogenous as possible not only in terms of 
their cellular content but also in terms of the distribution of infectivity associated with the BSE 
agent in blood. After pooling and gentle mixing to ensure homogeneity, the pooled LR-RCC 
was allowed to flow into the transfer packs, resulting in two separate units of LR-RCC of 
approximately equal volume. One of the two LR-RCC units was transfused to a recipient 
sheep without further processing, following cross-matching of donor and recipient blood 
samples, as previously described.15  
 
The other LR-RCC unit was processed using the P-CAPT filter according to the 
manufacturer’s instructions. A P-CAPT filter and associated transfer pack was docked (using 
sterile conditions) to the LR-RCC unit, with tubing separating the two (of a standard length of 
15 cm). A stainless steel adjustable clamp was fitted to the tubing immediately below the P-
CAPT filter and closed completely prior to filtration. This was used to manage the flow rate of 
blood during the filtration process. The snap valve fitted inside the tubing between the LR-
RCC bag and the P-CAPT filter was opened to allow the flow of LR-RCC into the P-CAPT 
filter. Next, the adjustable stainless steel clamp was opened by a few (4-5) millimeters 
allowing controlled flow of LR-RCC through the P-CAPT filter and into the associated 
transfer pack, with the aim of ensuring that the filtration time took between 40 – 60 m (in line 
with recommendations from the manufacturer relating to blood contact time with the P-CAPT 
filter). The resultant LR-RCC-P-CAPT component was transfused to a recipient sheep, 
following cross-matching of donor and recipient blood samples.  
 
Specifications of LR-RCC and LR-RCC-P-CAPT components used for transfusion  
The volumes of each unit of whole blood collected, LR-RCC and LR-RCC-P-CAPT 
components prepared (ml)  were determined by subtracting the weight of an empty collection 
bag from the filled weight of each component and dividing by the specific gravities of 1.06 for 
whole blood and red cell concentrate, as previously described.17  Similarly, the methods for 
determining leucocyte counts and the distribution of plasma in the RCC, LR-RCC and LR-
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RCC-P-CAPT components have already been described in detail.17 The time (in minutes) 
taken for leucoreduction and P-CAPT filtration was also recorded. 
 
Leucocyte evaluation using quantitative real-time PCR of sheep CD45 
CD45 antigen is a universal and specific marker of leucocytes in blood. In addition to the BD 
Leucocount technique previously described,17 residual numbers of leucocytes from sheep 
blood samples were determined by quantitative real-time PCR (qPCR) of CD45 genomic 
DNA (gDNA) by two separate methods using an Applied Biosystems 7000 Sequence 
Detection System (Life Technologies).  Small volume aliquots (0.5 – 1ml) of each unit of 
RCC (prior to leucoreduction), LR-RCC and LR-RCC-PCAPT were stored at -20 ˚C at the 
time of preparation. gDNA was extracted from 50 µl of sheep blood using the Invitrogen 
ChargeSwitch gDNA Sheep Blood Kit (Life Technologies), and two PCR methods were used 
to quantitate gDNA, Power SYBR Green PCR (Applied Biosystems, Life Technologies, 
Paisley,  UK) and Taqman Universal PCR (Life Technologies),  according to the 
manufacturer's protocols. The primers were designed using the mRNA sequence of sheep 
CD45, which was identified from a blast search of the sheep genome v2.0 
http://www.livestockgenomics.csiro.au/sheep/oar2.0.php against the bovine homologue of 
human CD45 (NM_001206523.1). The forward primer was 5'-GCACCTACATCGGCATCGA, 
and the reverse primer 5'-CGTAGACGTCCACCTTGTTCTCT.  The number of leucocytes in 
each sample was calculated from the amplified gDNA by comparison against a standard 
curve of qPCR amplified CD45 from samples containing gDNA of known concentration (0.6 
pg - 60 ng) assuming one cell contained 6.6pg of DNA.   
 
Recipient sheep 
As for donor sheep, recipient sheep were maintained and monitored for clinical signs of BSE 
infection until they reached defined humane end points or were culled for other reasons. 
Samples of recto-anal mucosa-associated lymphoid tissues (RAMALT) were collected at 
intervals to monitor for pre-clinical infection, as previously described.54 At post mortem, 
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samples of brain and lymphoid tissues (tonsil, spleen, ileal Peyer’s patch, mesenteric lymph 
node, prescapular lymph node) were collected and either fixed in neutral buffered formalin or 
frozen at -80 oC. 
 
Detection of disease-associated PrP in tissues by Western blotting and 
immunohistochemistry  
Proteinase K (PK)-resistant PrPSc in brain  and lymphoid tissues was detected using 
established Western blot methods, probing with the monoclonal antibody (mAb) ROS-BC6 
(0.5 µg/ml) as previously described.17,55,56 Hyperfilm (GE Healthcare, Buckinghamshire, UK) 
was scanned and the digital image processed using Adobe Photoshop. Image processing 
was restricted to cropping, preparation of composite figures and annotation. 
 
Formalin-fixed sections of brain and lymphoid tissues were also analysed for PrPd deposition 
by immunohistochemistry using mAbs ROS-IH956 and BG4, as previously described. The 
monoclonal antibodies were applied and incubated overnight - ROS-IH9 (0.5 µg/ml at 4oC) 
or BG4 (1.25 µg/ml at ambient temperature). Each assay included known BSE positive and 
negative control tissues sections to verify the sensitivity and specificity of the procedure. 
Immunohistochemical staining of rectal biopsy samples were performed as previously 
described, using the mAb R145.54,57  
 
Results 
Confirmation of BSE infection in blood donors 
The seven sheep selected as blood donors for this study showed clinical signs typically 
associated with BSE infection, including pruritus and ataxia, with incubation periods ranging 
from approximately 800 to 1100 days.  Brain and peripheral lymphoid tissues from each 
donor tested positive for the presence of abnormal prion protein by Western blotting and 
immunohistochemistry. Figure 1 (A-C) shows positive staining in the dorsal motor nuclei of 
the vagus nerve (DMNV) of three donors with widespread, diffuse extra-cellular PrPd 
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labelling evident in each animal. The staining pattern is consistent with that seen in the 
positive control section (known BSE sheep sample, panel H) and distinct from that seen in 
the negative control section (known uninfected control sample, panel I), where no PrPd 
labelling is evident. Two antibodies were used to confirm and validate the experimental 
outcomes (figure S2). The same PrPd staining profile was observed in the other BSE positive 
donors (not shown). 
 
Transfusion components meet required specifications 
Table 2 show the parameters measured for each unit of whole blood collected from the 
donors and when processed to LR-RCC and LR-RCC-P-CAPT, including volumes and 
filtration times. Other parameters, such as the haematocrit and percentage of plasma in 
different components, were measured to assess the consistency of components prepared 
from different donors (data not shown), and did not differ significantly from those previously 
reported.17 
 
Following leucoreduction, the number of leucocytes in each paired unit of LR-RCC and LR-
RCC-P-CAPT was measured by flow cytometry and by quantitative real time-PCR for the 
CD45 gene expressed by all leucocytes. Table 2 shows the residual number of leucocytes in 
the LR-RCC and LR-RCC-P-CAPT units respectively, determined using the cytometer 
method.  All of the units tested contained less than 1 x 106 leucocytes / unit, and thus met 
the specification for human leucoreduced blood components.58 The results of the CD45 
qPCR were similar for samples from all donors, with estimated numbers of leucocytes 
approximately 3 logs less than that seen in the RCC units (data not shown), providing 
confirmatory evidence of adequate leucoreduction in units where it was not possible to 
obtain a leucocyte count by cytometry (donors N220, N259).  
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Infectivity associated with P-CAPT-filtered leucoreduced red cells 
Table 3 shows the timing of and outcome of RAMALT biopsies in euthanized and surviving 
transfusion recipients.  The only recipients found to have positive staining for abnormal PrPd 
in lymphoid follicles within biopsies were P524 and P511, which received paired LR-RCC 
and LR-RCC-P-CAPT components (respectively) from donor N220. Sheep P511 had three 
positive biopsy results from samples collected between 676 and 942 days post infection 
(representing 64% - 90% of the interval between transfusion and post mortem = survival 
period), while P524 had a single positive biopsy, which was collected close to the time when 
it developed clinical signs (92% of survival period). No further biopsies were undertaken as it 
has been observed that with age and in the absence of antigenic stimulus the follicles 
regress and become more scarce (data not shown). 
 
The same two sheep (P524, P511) were later euthanized following the demonstration of 
definite or suspect clinical signs associated with BSE. Two additional recipient sheep (P548, 
P467) were culled for welfare reasons. Immunohistochemistry and Western blotting 
performed on brain and lymphoid tissue samples confirmed that P524 and P511 were 
infected with BSE, while P548 and P467 were not. Figure 1 shows the pattern of abnormal 
prion protein deposition in the DMNV from recipient sheep P524 (panel G) and P511 (panel 
D), which is consistent with seen in their donor (N220, panel A), and similar to that 
previously reported for sheep experimentally infected with BSE. Figure 2  shows Western 
blots of PK-resistant PrPSc prepared from brain and lymphoid tissues from the clinically 
positive (P524, P511) and clinically negative (P467, P548) sheep. PK-resistant PrPSc was 
identified in brain and most lymphoid tissues tested in P524, and in brain, spleen and ileal 
Peyer’s patch of P511.   No PK-resistant PrPSc was detected in brain or lymphoid tissue in 
recipients P467 or P548 both of which received leucoreduced red cell concentrates from 
donors N245 and N218 respectively. Taken together, the results confirm that the only 
transfusion recipients that have shown clinical and/or pathological evidence of infection are 
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P524 (LR-RCC recipient) and P511 (LR-RCC-P-CAPT recipient), which both received 
components from donor N220. 
 
Discussion 
We undertook an independent evaluation to assess the qualitative effects of prion reduction 
following P-CAPT filtration of leucoreduced red cell concentrates compared to leucoreduced 
red cell concentrates alone. Unique to this study is that the source components are 
endogenously infected red cell concentrates from a large animal model. Out of fourteen 
recipients of LR-RCC or LR-RCC-P-CAPT, we observed infection and clinical disease in two 
recipients of paired components from the same donor.  
 
Due to the limitations in blood volume that can be collected from an individual sheep at one 
time, we were unable to carry out transfusions of non-leucoreduced RCC for direct 
comparison of transmission rates. However, in the related leucodepletion study, similar 
volumes of RCC prepared from BSE-infected donors at pre-clinical time points (30% - 50% 
of incubation period) transmitted infection to eight out of twenty-one recipients (38% attack 
rate), while LR-RCC transmitted to three out of twelve (25%) recipients (unpublished data). 
There is evidence from previous sheep studies showing that the probability of transmission 
of BSE or scrapie by blood transfusion increases as donors progress towards the clinical 
phase of infection,16,59 probably as a result of increasing titres of infectivity, and that RCC 
collected from scrapie-infected sheep in the late pre-clinical period can infect 100% of 
recipients.42 In support of this, the donor sheep (N220) that transmitted infection in the 
current study, also provided blood components at a pre-clinical time point (37% of survival 
period), which failed to transmit infection to their respective recipients (see Table S1). 
 
If we accept that the transmission rate in recipients of non-leucoreduced RCC from clinical 
donors would be greater than 38% and possibly as high as 100%, the fact that only one out 
of seven recipients of LR-RCC became infected indicates that leucoreduction alone reduces 
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the risk of transmission. Since infection was seen in the paired recipient of LR-RCC-P-CAPT 
from the same donor, it may tentatively be concluded that prion reduction by filtration does 
not provide an additional benefit to leucoreduction in reducing the risk of transmission. 
However, as the numbers of animals in the study are too small to give statistical power, we 
are unable to provide quantitative analysis of the level of risk reduction associated with prion 
filtration compared to leucoreduction alone. In addition, since we lack a suitable bioassay 
host (e.g. transgenic mouse) for quantifying BSE infectivity in sheep blood, we cannot 
provide estimates of titre before and after leucodepletion and prion filtration that would allow 
calculation of prion clearance values. Our findings are similar to those reported following 
blood transfusions from scrapie-infected sheep,42 in which one out of five recipients of 
leucoreduced red blood cells and one out of five recipients of leucoreduced and prion filtered 
red blood cells showed evidence of infection when culled at the end of the experiment (but 
did not develop clinical disease). The latter study tested the effect of the Leukotrap (Pall) and 
KASEI (Asahi) filters, but not the P-CAPT filter. 
 
At present, the only peer-reviewed data available on the use of the P-CAPT filter relate to its 
application for removal of exogenous and endogenous infectivity associated with 263K 
hamster scrapie. Studies using hamster brain homogenate spiked into a full unit of human 
leucoreduced red blood indicated that processing using the P-CAPT filter resulted in 
approximately 3 log reduction in infectivity39. However, it has been shown that as little as 200 
microlitres of intravenously administered blood can transmit infection between scrapie-
infected sheep, despite very low infectious titres estimated by intracerebral inoculation of 
blood into transgenic mice expressing sheep PrP, while the equivalent minimal infectious 
dose of brain-derived scrapie for sheep by the intravenous route is about 1000 times 
greater.20 This implies that results obtained from experiments using exogenous spikes of 
brain-derived infectivity to measure prion clearance by various processes may not accurately 
predict effects on endogenous infectivity.   Evaluation of the test resins used to develop the 
P-CAPT filter showed that a combination of leucoreduction and prion filtration reduced 
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endogenous infectivity in a unit of hamster whole blood by more than 1.22 log10ID
33. Another 
recent study, in which 2 units of leucoreduced red cells prepared from scrapie-infected 
hamsters were filtered using the P-CAPT device, showed an overall reduction in infectivity of 
approximately 1.4 log10ID, but concluded that there was residual infectivity of around 0.2 
ID/ml in the prion filtered blood (written communication; Dr. J.M. Sutton, September 2014). 
 
Leucoreduction of scrapie-infected hamster blood alone has been estimated to remove up to 
approximately 70% of endogenous infectivity, with the remainder being plasma-associated. 
However, transfusion experiments using prion-infected sheep and deer suggest that the 
infectivity in plasma is much lower in these species, and may be largely cell-
associated.17,19,42 The single case of “sub-clinical” vCJD infection identified in a person with 
haemophilia was thought most likely to have been caused by documented exposure to 
plasma products derived from a vCJD patient, which suggests that human plasma can also 
be infectious.28 These apparent species differences may reflect host-specific variation in the 
distribution of endogenous infectivity, or may arise from differences in the protocols used for 
preparation of components in the various studies. In this study, it is possible that the 
transmission of infection by LR-RCC and LR-RCC-P-CAPT components could be explained 
by infectivity associated with residual plasma and/or the small numbers of leucocytes 
remaining following leucoreduction and prion filtration. However, comparable levels of 
leucoreduction were achieved in components from all seven donors, but only one (N220) 
transmitted the infection, suggesting that this sheep may have had unusually high titres of 
blood borne infectivity. 
 
Ten of the sheep that were transfused with either LR-RCC or LR-RCC-P-CAPT are alive, 
with current survival periods ranging from 1710 to 1984 days post infection (Table 1). There 
is as yet no clear evidence, from clinical observations and the results of rectal biopsies, that 
any of these sheep are infected with BSE. The incubation periods of confirmed BSE-infected 
transfusion recipients from our ongoing leucodepletion study,17 are 1018 ± 188 days (mean ± 
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standard deviation) for 141LF genotype sheep (n = 25) and 705 ± 120 days for 141FF sheep 
(n =15) respectively (unpublished data). For comparison, the majority (9/10) of the surviving 
recipients in this experiment are 141LF (mean survival period = 1884 ± 118 days post 
infection), with a single 141FF recipient (survival period = 1773 days post infection). These 
survival periods represent a difference from the observed incubation periods of more than 4 
standard deviations of the mean, suggesting that it is unlikely that the remaining sheep will 
develop clinical signs. However, it is possible that they will show signs of infection when they 
are culled, even in the absence of clinical disease. Their prolonged survival after transfusion 
is consistent with a substantial reduction in infectivity associated with leucoreduction alone 
or in combination with prion filtration. 
 
In conclusion, we have demonstrated that, for one out of seven BSE-infected sheep used as 
blood donors, P-CAPT filtration of leucoreduced red cell concentrates did not remove all 
endogenous infectivity, resulting in infection and clinical disease in the transfused recipient. 
This supports the view that the filter cannot be assumed to prevent transmission of vCJD by 
blood transfusion. 
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Figure legends 
Figure 1: Immunohistochemical labelling of PrPd to confirm BSE infection. This figure 
shows a series of representative images taken of the dorsal motor nucleus of the vagus 
nerve (DMNV, brain), labelled with the PrP monoclonal antibody BG4. Panels A, B and C are 
from BSE-infected donor sheep N220, N245 and N218, respectively. Panels D, E, F and G 
are from recipient sheep P511, P467, P548 and P524 respectively. Panel H – positive 
control; sheep infected with BSE. Panel I – negative control; uninfected sheep. Positive PrPd 
labelling, comparable to that of the positive control (panel H), is seen in all three donors (A-
C), and in the paired recipients of blood components from donor N220, P511 (panel D) and 
P524 (panel G). Scale bar = 100 µm. 
 
Figure 2: Western blot detection of PrPSc for confirmation of infection in transfusion 
recipients. Proteinase K-resistant PrPSc was prepared from PK digested and NAPTA 
precipitated tissue homogenates. Tissues from euthanised recipients P524, P511, P467 and 
P548 were examined. Immunoblots were probed with the antibody ROS-BC6 (0.5µg/ml). 
Tissues analysed were medulla (pre-diluted 1:10 before loading, lane 1), neat extracts of 
spleen (lane 2), pre-scapular lymph node (lane 3), mesenteric lymph node (lane 4), distal 
ileal payer patches (lane 5) and tonsil (lane 6). Molecular weight markers are shown in kDa 
on the left hand side of the immunoblots and the exposure time was 6 minutes.  
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Table 1: Details of donor and recipient sheep 
 
 
*All donors were culled, upon reaching defined clinical endpoints associated with BSE infection, immediately after two units of whole blood was 
collected (i.e. on the day of blood donation). 
 †Survival periods were calculated as the number of days between the time of infection (by oral route for donors or by transfusion for recipients) 
and euthanasia OR 3rd October 2014 for sheep that are still alive (indicated by the ‡).  
§ LR-RCC = leucoreduced red cell concentrate;  LR-RCC-P-CAPT = P-CAPT filtered leucoreduced red cell concentrate. 
Donor details* Recipient details 
 
Sheep 
ID 
PRNP 
codon 
141  
genotype 
†Survival period  
(days post 
 infection, 
dpi) 
§Component 
Sheep 
ID 
 
PRNP 
codon 
141 
genotype 
†Survival  
period  
(dpi) 
Reason for cull Status 
N220 
 
FF 
 
797 
 
LR-RCC P524 LF 732 
Welfare (suspect 
clinical) 
BSE +ve 
LR-RCC-P-CAPT P511 FF 1049 Clinical BSE +ve 
N218 
 
FF 
 
840 
 
LR-RCC P548 FF 1130 Welfare BSE -ve 
LR-RCC-P-CAPT P466 LF 1984‡ NA Alive 
N245 
 
LF 
 
959 
 
LR-RCC P467 LF 573 Welfare BSE -ve 
LR-RCC-P-CAPT P461 LF 1981‡ NA Alive 
N180 
 
FF 
 
817 
 
LR-RCC Q391 LF 1970‡ NA Alive 
LR-RCC-P-CAPT Q397 LF 1970‡ NA Alive 
N258 
 
LL 
 
944 
 
LR-RCC P494 LF 1927‡ NA Alive 
LR-RCC-P-CAPT P304 LF 1927‡ NA Alive 
N178 
 
LF 
 
1168 
 
LR-RCC P541 LF 1774‡ NA Alive 
LR-RCC-P-CAPT P465 FF 1773‡ NA Alive 
N259 
 
LF 
 
1076 
 
LR-RCC P473 LF 1710‡ NA Alive 
LR-RCC-P-CAPT P280 LF 1710‡ NA Alive 
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Table 2: Specifications of blood components transfused to recipients 
 
*Components prepared from unit 1 (U1) = leucoreduced and P-CAPT-filtered red cells (LR-RCC-P-CAPT).  
†Components from unit 2 (U2) = leucoreduced red cells (LR-RCC).  
‡NA - Leucocyte count not assessed due to equipment failure on the day these units were processed. 
§Components which are lower in volume compared to the specifications for human equivalents. Acceptable volume specifications in human 
transfusion practice are 468-558ml for a unit of whole blood and 220-340ml for red cell concentrates.  
‖ The 0 events recorded for the LR-RCC from donor N259 does not mean that the units contained no leucocytes but rather that the residual 
numbers were below the limit of detection of the assay, 
 
Component 
parameters 
Donor ID 
N220 N218 N245 N180 N258 N178 N259 
U1* U2† U1* U2† U1* U2† U1* U2† U1* U2† U1* U2† U1* U2† 
Volume whole 
blood (ml) 
535 517 502 467§ 455§ 503 417§ 377§ 485 490 426§ 505 447§ 499 
Leucofiltration 
time (minutes) 
22 23 18 16 38 22 14 10 19 12 15 19 35 16 
P-CAPT 
filtration time 
(minutes) 
63  - 45  - 70  - 52  - 65  - 56  - 40  - 
Volume LR-RCC 
or LR-RCC- 
P-CAPT 
transfused (ml) 
289 262 297 284 288 259 251 228 259 258 286 220 247 205§ 
Leucocyte 
count (x 104 
cells/unit) 
NA‡ NA‡ 14 4.4 50 4.8 1.1 1.3 21 9.8 1.3 1.3 
 
0‖ 
 
0‖ 
24 
 
Table 3: Results of RAMALT biopsy in transfusion recipients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*NA – sheep P467 was euthanized before biopsies were collected. 
  
Recipient  
ID 
No. positive follicles / 
total follicles 
 (% positive) 
Sample time 
(days post 
infection) 
P524 29 / 29 (100%) 676 
P511 2 / 10 (20%) 676 
 11 / 23 (48%) 763 
 2 / 5 (40%) 942 
P548 0 / 20  587 
 0 / 12  853 
P466 0 / 28 587 
 0 / 12  853 
 0 / 9  1448 
P467 NA* NA* 
P461 0 / 24 589 
 0 / 36  850 
 0 / 4 1445 
Q391 0 / 30 573 
 0 / 8  839 
 0 / 8  1434 
Q397 0 / 14 573 
 0 / 6  839 
 0 / 2  1434 
P494 0 / 23 530 
 0 / 21  796 
 0 / 3  1391 
P304 0 / 3 530 
 0 / 0  796 
 0 / 2 1391 
P541 0 / 15 377 
 0 / 8  643 
 0 / 2  1238 
P465 0 / 31 376 
 0 / 13 642 
 0 / 4   1237 
P473 0 / 9 313 
 0 / 4 579 
 0 / 9  1174 
P280 0 / 10 313 
 0 / 4  579 
 0 / 13 1174 
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Figure 1. 
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Figure 2. 
 
 
 
